The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Financial Times TechEurope

The $15bn ‘viral’ AI start-up changing how American doctors treat patients

10.21

Founder of OpenEvidence chatbot says two-thirds of US physicians use the ad-powered tool, prompting a debate about patient care

Funding & deals

Read at Financial Times Tech ↗

One letter a week, starting soon.

Latest

The $15bn ‘viral’ AI start-up changing how American doctors treat patients

Related

LabsSoutheast Asia’s digital economy to hit $368 billion Google AI Blog

ValleyAI infrastructure management software startup ASI hits $3B valuation after raising $325M in funding SiliconANGLE

ValleySpaceX’s stock soars as Elon Musk reveals crushing earnings and revenue beat SiliconANGLE

ValleyArda Industries raises $232M to make production lines more adaptable SiliconANGLE

ValleyEka Robotics nets $150M at a $1.45B valuation for robot hands that sense force SiliconANGLE

AsiaWhy Anthropic has a major China problem ahead of its blockbuster IPO SCMP Tech